1
40
15
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ajog.2004.12.032" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ajog.2004.12.032</a>
Pages
1365–1367
Issue
5
Volume
192
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
Publisher
An entity responsible for making the resource available
American Journal of Obstetrics & Gynecology
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-05
Subject
The topic of the resource
Adult; Aged; Survival; Drug Administration Schedule; Human; Middle Age; Retrospective Design; Neoplasm Recurrence; Antineoplastic Agents; Combined; Kaplan-Meier Estimator; Drug Toxicity; Severity of Illness; Carboplatin – Administration and Dosage; Endometrial Neoplasms – Drug Therapy; Local – Drug Therapy; Paclitaxel – Administration and Dosage
Creator
An entity primarily responsible for making the resource
Akram T; Maseelall P; Fanning J
Description
An account of the resource
OBJECTIVE: The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer. STUDY DESIGN: This was a retrospective review of 18 consecutive patients with advanced (stage 4) or recurrent endometrial adenocarcinoma that had been treated with outpatient carboplatin and taxol. Taxol was delivered at 135 mg/m 2 over 3 hours, and carboplatin was delivery at an area under the curve of 5 over 1 hour. Cycles were repeated every 21 days. RESULTS: The overall response rate was 63% with 28% of patients who had a partial response and 35% of patients who had a complete response. Kaplan-Meier test was used to estimate the median survival time of 27 months and the median progression free survival time of 24 months. No patient had neutropenia, thrombocytopenia or grade 3 vomiting, neurosensory toxicity, or renal toxicity. CONCLUSION: Carboplatin and taxol for the treatment of advanced or recurrent endometrial cancer appear to be active regimens with minimal toxicity.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ajog.2004.12.032" target="_blank" rel="noreferrer noopener">10.1016/j.ajog.2004.12.032</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2005
Adult
Aged
Akram T
American Journal of Obstetrics & Gynecology
Antineoplastic Agents
Carboplatin – Administration and Dosage
Combined
Drug Administration Schedule
Drug Toxicity
Endometrial Neoplasms – Drug Therapy
Fanning J
Human
Kaplan-Meier Estimator
Local – Drug Therapy
Maseelall P
Middle Age
Neoplasm Recurrence
Paclitaxel – Administration and Dosage
Retrospective Design
Severity of Illness
Survival
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
5–15
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Improving Outcomes in Early-Stage Breast Cancer.
Publisher
An entity responsible for making the resource available
Oncology (08909091)
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-10-03
Subject
The topic of the resource
Physician-Patient Relations; Neoplasm Staging; Prognosis; Survival; Education; Practice Guidelines; Antineoplastic Agents; Adjuvant; Chemotherapy; Treatment Outcomes; Race Factors; Early Detection of Cancer; Lumpectomy; Continuing (Credit); Breast Neoplasms – Mortality; Breast Neoplasms – Pathology; Breast Neoplasms – Therapy; Breast Neoplasms – Classification; Breast Neoplasms – Psychosocial Factors; Hormonal – Therapeutic Use
Creator
An entity primarily responsible for making the resource
Glück Stefan; Mamounas Terry; Klem Jennifer
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Adjuvant
Antineoplastic Agents
Breast Neoplasms – Classification
Breast Neoplasms – Mortality
Breast Neoplasms – Pathology
Breast Neoplasms – Psychosocial Factors
Breast Neoplasms – Therapy
Chemotherapy
Continuing (Credit)
Early Detection of Cancer
Education
Glück Stefan
Hormonal – Therapeutic Use
Klem Jennifer
Lumpectomy
Mamounas Terry
Neoplasm Staging
Oncology (08909091)
Physician-Patient Relations
Practice Guidelines
Prognosis
Race Factors
Survival
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
1–8
Issue
2
Volume
6
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.
Publisher
An entity responsible for making the resource available
Clinical advances in hematology & oncology : H&O
Date
A point or period of time associated with an event in the lifecycle of the resource
2008
2008-02
Subject
The topic of the resource
Adult; Female; Humans; Middle Aged; Genotype; Clinical Trials as Topic; *Gene Expression Profiling; *Breast Neoplasms/diagnosis/genetics/therapy; Breast Neoplasms/classification/*drug therapy/*genetics/surgery; Gene Expression Profiling/*methods; Polymerase Chain Reaction/methods; Tamoxifen/therapeutic use; Receptors; Antineoplastic Agents; Adjuvant; Chemotherapy; Adjuvant/methods; Estrogen/analysis; Hormonal/therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P; Budd G Thomas; Miller Kathy D
Description
An account of the resource
Advances in breast cancer research have confirmed that this malignancy is not a single disease, but rather a collection of genetically distinct diseases with different treatment requirements. In recent years, several studies have confirmed the clinical validity of the Oncotype DX breast cancer assay, not only as a way to predict recurrence but also as a tool for determining therapeutic benefit from adjuvant chemotherapy. Recently, Drs. Terry Mamounas, G. Thomas Budd, and Kathy Miller answered questions about the Oncotype DX assay that are particularly relevant to routine clinical practice. This expert dialog provides a useful update and essential clinical insights about how, why, and when community oncologists may want to incorporate this multi-gene assay into their care of breast cancer patients. In addition, sample case studies offer tangible examples of the practical application of Oncotype DX.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Breast Neoplasms/diagnosis/genetics/therapy
*Gene Expression Profiling
2008
Adjuvant
Adjuvant/methods
Adult
Antineoplastic Agents
Breast Neoplasms/classification/*drug therapy/*genetics/surgery
Budd G Thomas
Chemotherapy
Clinical advances in hematology & oncology : H&O
Clinical Trials as Topic
Estrogen/analysis
Female
Gene Expression Profiling/*methods
Genotype
Hormonal/therapeutic use
Humans
Mamounas Eleftherios P
Middle Aged
Miller Kathy D
Polymerase Chain Reaction/methods
Receptors
Tamoxifen/therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
1613–1618
Issue
10
Volume
5
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Anthocyanin-rich black currant extract suppresses the growth of human hepatocellular carcinoma cells.
Publisher
An entity responsible for making the resource available
Natural product communications
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-10
Subject
The topic of the resource
Humans; Cell Proliferation/drug effects; Fruit/chemistry; *Phytotherapy; Plant Extracts/pharmacology/therapeutic use; Hep G2 Cells; Antioxidants/*therapeutic use; *Ribes/chemistry; Liver Neoplasms/*prevention & control; Carcinoma; Drug Evaluation; Preclinical; Antineoplastic Agents; Hepatocellular/*prevention & control; Phytogenic/analysis
Creator
An entity primarily responsible for making the resource
Bishayee Anupam; Haznagy-Radnai Erzsebet; Mbimba Thomas; Sipos Peter; Morazzoni Paolo; Darvesh Altaf S; Bhatia Deepak; Hohmann Judit
Description
An account of the resource
Dietary antioxidants, such as anthocyanins, are helpful in the prevention and control of various diseases by counteracting the imbalance of oxidative and antioxidative factors in the living systems. Black currant (Ribes nigrum L., Grossulariaceae) is known to contain high amounts of anthocyanins (250 mg/100 g fresh fruit). Black currant fruits have been used in Asian and European traditional medicine for the treatment of a variety of diseases. Black currant extract has recently been found to be the second most effective amongst nine different berry extracts studied for their free radical scavenging activity. Constituents present in black currant juice have been found to exert a number of health-promoting effects, including immunomodulatory, antimicrobial and antiinflammatory actions, inhibition of low-density lipoprotein, and reduction of cardiovascular diseases. Although antioxidant and antiinflammatory effects of black currant juice could be of value in preventing and treating oxidative stress- and inflammation-driven cancers, no experimental evidence is available to now. The objective of the present study was to evaluate the potential antiproliferative effects of black currant fruit skin extract against HepG2 human liver cancer cells. The aqueous extract yielded an anthocyanin-rich fraction with cyanidin-3-O-rutinoside as one of the major anthocyanins. This fraction exhibited a potent cytotoxic effect on HepG2 cells and this effect was more pronounced than that of delphinidin and cyanidin, two major aglycones of anthocyanins present in black currant. Our results indicate, for the first time, that black currant skin containing an anthocyanin-rich fraction inhibits the proliferation of liver cancer cells, possibly due to additive as well as synergistic effects. This product could be useful in the prevention and treatment of human hepatocellular carcinoma.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Phytotherapy
*Ribes/chemistry
2010
Antineoplastic Agents
Antioxidants/*therapeutic use
Bhatia Deepak
Bishayee Anupam
Carcinoma
Cell Proliferation/drug effects
Darvesh Altaf S
Department of Pharmaceutical Sciences
Drug Evaluation
Fruit/chemistry
Haznagy-Radnai Erzsebet
Hep G2 Cells
Hepatocellular/*prevention & control
Hohmann Judit
Humans
Liver Neoplasms/*prevention & control
Mbimba Thomas
Morazzoni Paolo
Natural product communications
NEOMED College of Pharmacy
Phytogenic/analysis
Plant Extracts/pharmacology/therapeutic use
Preclinical
Sipos Peter
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.4158/EP.10.6.483" target="_blank" rel="noreferrer noopener">http://doi.org/10.4158/EP.10.6.483</a>
Pages
483–486
Issue
6
Volume
10
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A case of Riedel's thyroiditis treated with tamoxifen: another successful outcome.
Publisher
An entity responsible for making the resource available
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-12
Subject
The topic of the resource
Adult; Female; Humans; Magnetic Resonance Imaging; Goiter/*drug therapy/pathology; Hypothyroidism/drug therapy/pathology; Tamoxifen/*administration & dosage; Thyroiditis/*drug therapy/pathology; Antineoplastic Agents; Hormonal/*administration & dosage
Creator
An entity primarily responsible for making the resource
Jung Yiechul J; Schaub Carl R; Rhodes Ronald; Rich Frank A; Muehlenbein Stephen J
Description
An account of the resource
OBJECTIVE: To report a case of Riedel's thyroiditis, which was successfully treated with tamoxifen. METHODS: We present the clinical, laboratory, and imaging findings and describe the clinical course of a patient with Riedel's thyroiditis. RESULTS: A 40-year-old woman presented with hypothyroidism and a large goiter, which was unresponsive to hormone replacement therapy. Magnetic resonance imaging confirmed the presence of an enlarged thyroid gland, more pronounced on the right than on the left. The patient had progressive discomfort attributable to compressive symptoms in the neck. Surgical exploration of the neck disclosed a hard, immobile thyroid mass, which could not be resected because of adherence to surrounding structures. Biopsy of the thyroid and of the muscles of the neck revealed Riedel's thyroiditis. Treatment with tamoxifen, in a dosage of 20 mg twice a day for more than 1(1/2) years, completely resolved the neck mass (substantiated by follow-up magnetic resonance imaging) and relieved the signs and symptoms of compression of the neck. CONCLUSION: Tamoxifen treatment is effective in resolving the mass and compression in Riedel's thyroiditis.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.4158/EP.10.6.483" target="_blank" rel="noreferrer noopener">10.4158/EP.10.6.483</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Adult
Antineoplastic Agents
Department of Family & Community Medicine
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Female
Goiter/*drug therapy/pathology
Hormonal/*administration & dosage
Humans
Hypothyroidism/drug therapy/pathology
Jung Yiechul J
Magnetic Resonance Imaging
Muehlenbein Stephen J
NEOMED College of Medicine
Rhodes Ronald
Rich Frank A
Schaub Carl R
Tamoxifen/*administration & dosage
Thyroiditis/*drug therapy/pathology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3816/cbc.2001.s.004" target="_blank" rel="noreferrer noopener">http://doi.org/10.3816/cbc.2001.s.004</a>
Pages
S20–30
Volume
2 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer.
Publisher
An entity responsible for making the resource available
Clinical breast cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
2001-10
Subject
The topic of the resource
Female; Humans; Prognosis; Decision Making; Clinical Trials as Topic; Neoadjuvant Therapy; Tamoxifen/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Breast Neoplasms/*drug therapy/surgery; Diphosphonates/therapeutic use; Ovary/drug effects/physiology; Taxoids/therapeutic use; Antineoplastic Agents; Adjuvant; Chemotherapy; Hormonal/*therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas E P
Description
An account of the resource
In patients with operable breast cancer, adjuvant hormonal therapy and adjuvant chemotherapy result in significant and long-term reductions in the rates of disease recurrence and death. These reductions are evident in both patients with node-negative as well as in those with node-positive disease. However, several issues in the adjuvant treatment of breast cancer still remain unresolved. These issues were recently considered at the 2000 National Institutes of Health (NIH) Consensus Development Conference, which reviewed the current state of knowledge on adjuvant therapy and outlined strategies for future research. In the area of adjuvant hormonal therapy, tamoxifen is still the gold standard, and present evidence supports the use of tamoxifen for patients with estrogen receptor (ER)-positive tumors irrespective of age, menopausal status, nodal status, or tumor size. Optimal duration of tamoxifen therapy is about 5 years. Future research directions include evaluating the benefit of extending tamoxifen beyond 5 years, the contribution of ovarian ablation, and the role of hormonal manipulations involving selective ER modulators and aromatase inhibitors instead of or in addition to tamoxifen. In the area of adjuvant chemotherapy, polychemotherapy regimens have been consistently found to be superior to single agents, and anthracycline-containing regimens produce a small but statistically significant improvement in survival when compared with regimens not containing an anthracycline. High-dose adjuvant chemotherapy with stem cell support has not been proven superior to standard regimens. Neoadjuvant therapy offers the possibility of testing in vivo the sensitivity of individual tumors to particular cytotoxic regimens and, hence, of improving ultimate disease control, as well as reducing the extent of local therapy. The contribution and optimal integration of taxanes in the adjuvant setting are yet to be established but are the subject of intense research effort. Similarly, novel targeted therapies such as trastuzumab and bisphosphonates are currently being evaluated in adjuvant studies
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3816/cbc.2001.s.004" target="_blank" rel="noreferrer noopener">10.3816/cbc.2001.s.004</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2001
Adjuvant
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy/surgery
Chemotherapy
Clinical breast cancer
Clinical Trials as Topic
Decision Making
Diphosphonates/therapeutic use
Female
Hormonal/*therapeutic use
Humans
Mamounas E P
Neoadjuvant Therapy
Ovary/drug effects/physiology
Prognosis
Tamoxifen/administration & dosage
Taxoids/therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3109/13880209.2012.749922" target="_blank" rel="noreferrer noopener">http://doi.org/10.3109/13880209.2012.749922</a>
Pages
668–674
Issue
5
Volume
51
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Antitumor activities of extracts from selected desert plants against HepG2 human hepatocellular carcinoma cells.
Publisher
An entity responsible for making the resource available
Pharmaceutical biology
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-05
Subject
The topic of the resource
Humans; Time Factors; Hep G2 Cells; Desert Climate; Inhibitory Concentration 50; Liver Neoplasms/*drug therapy/pathology; Plant Extracts/administration & dosage/*pharmacology; Tetrazolium Salts/chemistry; Thiazoles/chemistry; Carcinoma; Dose-Response Relationship; Drug; Plants; Antineoplastic Agents; Aerial; Hepatocellular/*drug therapy/pathology; Medicinal/chemistry; Phytogenic/administration & dosage/*pharmacology; Plant Components
Creator
An entity primarily responsible for making the resource
Thoppil Roslin J; Harlev Eli; Mandal Animesh; Nevo Eviatar; Bishayee Anupam
Description
An account of the resource
CONTEXT: Phytochemicals are produced by desert plants to protect themselves against stressful environments. They have been shown to be useful in preventing and fighting adverse pathophysiological conditions and complex diseases, including cancer. Although many desert plants have been investigated for their antitumor properties, a large number of them still remain to be explored for possible therapeutic applications in oncologic diseases. OBJECTIVE: To screen the antitumor effects of selected desert plants, namely Achillea fragrantissima (Forssk.) Sch. Bip. (Compositae), Ochradenus baccatus Delile (Resedaceae), Origanum dayi Post (Lamiaceae), Phlomis platystegia Post (Lamiaceae) and Varthemia iphionoides Boiss (Compositae), against an in vitro tumor model utilizing HepG2 human hepatocellular carcinoma cells. MATERIALS AND METHODS: The aqueous extracts of aerial parts of the aforementioned plants were prepared and used for the in vitro experiments. The HepG2 cells were exposed to varying concentrations (0-4 mg/mL) of each plant extract for 24 or 48 h and the cytotoxicity was measured by the MTT assay. RESULTS: Following 24 h exposure, O. dayi extract exhibited a substantial antiproliferative effect in HepG2 cells (IC50 = 1.0 mg/mL) followed by O. baccatus (IC50 = 1.5 mg/mL). All plant extracts displayed cytotoxicity following 48 h exposure. Nevertheless, a substantial effect was observed with O. dayi (IC50 = 0.35 mg/mL) or O. baccatus (IC50 = 0.83 mg/mL). CONCLUSION: The aqueous extracts from aerial parts of O. dayi and O. baccatus possess antitumor effects against human liver cancer cells. These desert plants represent valuable resources for the development of potential anticancer agents.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3109/13880209.2012.749922" target="_blank" rel="noreferrer noopener">10.3109/13880209.2012.749922</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
Aerial
Antineoplastic Agents
Bishayee Anupam
Carcinoma
Desert Climate
Dose-Response Relationship
Drug
Harlev Eli
Hep G2 Cells
Hepatocellular/*drug therapy/pathology
Humans
Inhibitory Concentration 50
Liver Neoplasms/*drug therapy/pathology
Mandal Animesh
Medicinal/chemistry
Nevo Eviatar
Pharmaceutical biology
Phytogenic/administration & dosage/*pharmacology
Plant Components
Plant Extracts/administration & dosage/*pharmacology
Plants
Tetrazolium Salts/chemistry
Thiazoles/chemistry
Thoppil Roslin J
Time Factors
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3109/1061186X.2011.589435" target="_blank" rel="noreferrer noopener">http://doi.org/10.3109/1061186X.2011.589435</a>
Pages
837–845
Issue
9
Volume
19
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers.
Publisher
An entity responsible for making the resource available
Journal of drug targeting
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-11
Subject
The topic of the resource
Humans; Male; Animals; Mice; *Drug Delivery Systems; Rats; Cell Line; Nanoparticles; Permeability; Particle Size; Delayed-Action Preparations; Blood-Brain Barrier/metabolism; Adenosine Triphosphatases/metabolism; Brain Neoplasms/drug therapy; Cell Death/drug effects; Coumarins/administration & dosage/pharmacokinetics; Glioma/drug therapy/pathology; Glutathione/*chemistry; Microtubules/metabolism; Paclitaxel/administration & dosage/*pharmacokinetics/pharmacology; Thiazoles/administration & dosage/pharmacokinetics; Tubulin/metabolism; Inbred C57BL; Tumor; ATP Binding Cassette Transporter; Antineoplastic Agents; Member 1/metabolism; Subfamily B; Phytogenic/administration & dosage/*pharmacokinetics/pharmacology
Creator
An entity primarily responsible for making the resource
Geldenhuys Werner; Mbimba Thomas; Bui Thong; Harrison Kimberly; Sutariya Vijaykumar
Description
An account of the resource
Paclitaxel is not effective for treatment of brain cancers because it cannot cross the blood-brain barrier (BBB) due to efflux by P-glycoprotein (P-gp). In this work, glutathione-coated poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) of paclitaxel were developed for brain targeting for treatment of brain cancers. P-gp ATPase assay was used to evaluate the NP as potential substrates. The NP showed a particle size suitable for BBB permeation (particle size around 200 nm) and higher cellular uptake of the NP was demonstrated in RG2 cells. The
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3109/1061186X.2011.589435" target="_blank" rel="noreferrer noopener">10.3109/1061186X.2011.589435</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Drug Delivery Systems
2011
Adenosine Triphosphatases/metabolism
Animals
Antineoplastic Agents
ATP Binding Cassette Transporter
Blood-Brain Barrier/metabolism
Brain Neoplasms/drug therapy
Bui Thong
Cell Death/drug effects
Cell Line
Coumarins/administration & dosage/pharmacokinetics
Delayed-Action Preparations
Geldenhuys Werner
Glioma/drug therapy/pathology
Glutathione/*chemistry
Harrison Kimberly
Humans
Inbred C57BL
Journal of drug targeting
Male
Mbimba Thomas
Member 1/metabolism
Mice
Microtubules/metabolism
Nanoparticles
Paclitaxel/administration & dosage/*pharmacokinetics/pharmacology
Particle Size
Permeability
Phytogenic/administration & dosage/*pharmacokinetics/pharmacology
Rats
Subfamily B
Sutariya Vijaykumar
Thiazoles/administration & dosage/pharmacokinetics
Tubulin/metabolism
Tumor
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2741/3730" target="_blank" rel="noreferrer noopener">http://doi.org/10.2741/3730</a>
Pages
980–996
Volume
16
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer.
Publisher
An entity responsible for making the resource available
Frontiers in bioscience (Landmark edition)
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-01
Subject
The topic of the resource
Humans; Animals; Mice; Chemoprevention; Anticarcinogenic Agents/chemistry/*therapeutic use; Breast Neoplasms/*drug therapy/*prevention & control; Glycosides/therapeutic use; Oleanolic Acid/analogs & derivatives/therapeutic use; Triterpenes/*therapeutic use; Antineoplastic Agents; Phytogenic/therapeutic use
Creator
An entity primarily responsible for making the resource
Bishayee Anupam; Ahmed Shamima; Brankov Nikoleta; Perloff Marjorie
Description
An account of the resource
Breast cancer remains a major cause of death in the United States as well as the rest of the world. In view of the limited treatment options for patients with advanced breast cancer, preventive and novel therapeutic approaches play an important role in combating this disease. The plant-derived triterpenoids, commonly used for medicinal purposes in many Asian countries, posses various pharmacological properties. A large number of triterpenoids are known to exhibit cytotoxicity against a variety of tumor cells as well as anticancer efficacy in preclinical animal models. Numerous triterpenoids have been synthesized by structural modification of natural compounds. Some of these analogs are considered to be the most potent antiinflammatory and anticarcinogenic triterpenoids known. This review examines the potential role of natural triterpenoids and their derivatives in the chemoprevention and treatment of mammary tumors. Both in vitro and in vivo effects of these agents and related molecular mechanisms are presented. Potential challenges and future directions involved in the advancement of these promising compounds in the prevention and therapy of human breast cancer are also identified.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2741/3730" target="_blank" rel="noreferrer noopener">10.2741/3730</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
Ahmed Shamima
Animals
Anticarcinogenic Agents/chemistry/*therapeutic use
Antineoplastic Agents
Bishayee Anupam
Brankov Nikoleta
Breast Neoplasms/*drug therapy/*prevention & control
Chemoprevention
Frontiers in bioscience (Landmark edition)
Glycosides/therapeutic use
Humans
Mice
Oleanolic Acid/analogs & derivatives/therapeutic use
Perloff Marjorie
Phytogenic/therapeutic use
Triterpenes/*therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2174/138920112798868791" target="_blank" rel="noreferrer noopener">http://doi.org/10.2174/138920112798868791</a>
Pages
218–228
Issue
1
Volume
13
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Curcumin and liver cancer: a review.
Publisher
An entity responsible for making the resource available
Current pharmaceutical biotechnology
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
2012-01
Subject
The topic of the resource
Humans; Animals; Anticarcinogenic Agents/*therapeutic use; Antioxidants/therapeutic use; Anti-Inflammatory Agents/therapeutic use; Curcumin/*therapeutic use; Liver Neoplasms/*drug therapy/prevention & control; Carcinoma; Antineoplastic Agents; Hepatocellular/*drug therapy/prevention & control; Phytogenic/*therapeutic use
Creator
An entity primarily responsible for making the resource
Darvesh Altaf S; Aggarwal Bharat B; Bishayee Anupam
Description
An account of the resource
Primary liver cancer, also known as hepatocellular carcinoma (HCC), is one of the most lethal cancers having worldwide prevalence. Although most HCC cases are reported in the developing countries of Asia and Africa, there has been an alarming increase in HCC cases in Western Europe as well as United States. Chronic liver diseases, viral hepatitis, alcoholism as well as dietary carcinogens, such as aflatoxins and nitrosoamines, contribute to HCC. Liver transplantation as well as surgical resection at best offer limited treatment options. Thus, there exists a critical need to investigate and evaluate possible alternative chemopreventive and therapeutic strategies which may be effective in the control of liver cancer. HCC, most often, develops and progresses in a milieu of oxidative stress and inflammation. Phytochemicals, such as dietary polyphenols endowed with potent antioxidant as well as anti-inflammatory properties, provide a suitable alternative in affording alleviation of HCC. Curcumin, the principal polyphenolic curcuminoid, obtained from the turmeric rhizome Curcuma longa has long been used to cure several chronic ailments, such as neoplastic and neurodegenerative diseases. Studies suggest that curcumin may have antitumor, antioxidant, and anti-inflammatory properties. This article reviews the effects of curcumin in preclinical in vitro and in vivo models of HCC with particular emphasis to its antioxidant, apoptotic and anti-inflammatory effects as well as involvement in various molecular signaling mechanisms. This review also discusses potential challenges involved in the use of curcumin in HCC, such as bioavailability, pharmacokinetics, drug delivery as well as paucity of clinical studies.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2174/138920112798868791" target="_blank" rel="noreferrer noopener">10.2174/138920112798868791</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2012
Aggarwal Bharat B
Animals
Anti-Inflammatory Agents/therapeutic use
Anticarcinogenic Agents/*therapeutic use
Antineoplastic Agents
Antioxidants/therapeutic use
Bishayee Anupam
Carcinoma
Curcumin/*therapeutic use
Current pharmaceutical biotechnology
Darvesh Altaf S
Department of Pharmaceutical Sciences
Hepatocellular/*drug therapy/prevention & control
Humans
Liver Neoplasms/*drug therapy/prevention & control
NEOMED College of Pharmacy
Phytogenic/*therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1634/theoncologist.10-90002-9" target="_blank" rel="noreferrer noopener">http://doi.org/10.1634/theoncologist.10-90002-9</a>
Pages
9–17
Volume
10 Suppl 2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Can we approach zero relapse in breast cancer?
Publisher
An entity responsible for making the resource available
The oncologist
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-10
Subject
The topic of the resource
Female; Humans; Gene Expression Profiling; Prognosis; Recurrence; Disease-Free Survival; Lymph Nodes/pathology; Neoadjuvant Therapy; Aromatase Inhibitors/therapeutic use; Breast Neoplasms/mortality/pathology/*prevention & control/*therapy; Antineoplastic Agents; Adjuvant; Chemotherapy; Hormonal/*therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
Adjuvant hormonal therapy and adjuvant chemotherapy have contributed significantly to the falling rates of breast cancer mortality. The introduction of taxanes and aromatase inhibitors in the adjuvant setting represents recent important improvements. More recently, the demonstration of significant benefit in the adjuvant setting with novel molecular targeted therapies (such as trastuzumab [Herceptin; Genentech, Inc., South San Francisco, CA, http://www.gene.com]) is already beginning to have a substantial impact on the adjuvant treatment of patients with certain tumor characteristics (i.e., HER-2 positivity). Neoadjuvant treatment represents an approach that offers an intermediate end point (i.e., pathologic complete response) that can be used as a marker of therapeutic activity. Furthermore, the use of genomic profiling is starting to replace the traditional prognostic and predictive factors currently used to estimate risks for recurrence and response to particular adjuvant therapies. These recent developments have demonstrated that the notion of approaching zero relapse in breast cancer patients is now within our reach.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1634/theoncologist.10-90002-9" target="_blank" rel="noreferrer noopener">10.1634/theoncologist.10-90002-9</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2005
Adjuvant
Antineoplastic Agents
Aromatase Inhibitors/therapeutic use
Breast Neoplasms/mortality/pathology/*prevention & control/*therapy
Chemotherapy
Disease-Free Survival
Female
Gene Expression Profiling
Hormonal/*therapeutic use
Humans
Lymph Nodes/pathology
Mamounas Eleftherios P
Neoadjuvant Therapy
Prognosis
Recurrence
The oncologist
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1039/c2fo30058c" target="_blank" rel="noreferrer noopener">http://doi.org/10.1039/c2fo30058c</a>
Pages
795–809
Issue
8
Volume
3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The health benefits of blackcurrants.
Publisher
An entity responsible for making the resource available
Food & function
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
2012-08
Subject
The topic of the resource
*Health Promotion; *Ribes/chemistry; Anthocyanins/analysis; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Fatty Acids; Flavonoids/analysis; Fruit/chemistry; Humans; Phytogenic; Phytotherapy; Plant Extracts/adverse effects/pharmacokinetics/pharmacology; Unsaturated/analysis
Creator
An entity primarily responsible for making the resource
Gopalan Ashwin; Reuben Sharon C; Ahmed Shamima; Darvesh Altaf S; Hohmann Judit; Bishayee Anupam
Description
An account of the resource
The blackcurrant (Ribes nigrum L., Grossulariceae), a small, perennial shrub native to central Europe and northern Asia, is cultivated throughout the world, including the United States. In addition to its anecdotal use in traditional herbal medicine, modern laboratories have demonstrated the potent anti-inflammatory, antioxidant and antimicrobial effects of blackcurrant constituents on a myriad of disease states. The properties of the blackcurrants are conferred from its biochemical constituents, some of which include anthocyans (specifically delphinidin-3-O-glucoside, delphinidin-3-O-rutinoside, cyanidin-3-O-glucoside and cyanidin-3-O-rutinoside), flavonols, phenolic acids and polyunsaturated fatty acids. A plethora of studies have been published with regards to its various therapeutic applications. This article attempts to summarize these studies, providing a general overview of the research in this field. Several studies focus on the therapeutic potential of blackcurrants with regards to hypertension and other cardiovascular-associated illnesses, neoplastic, neurodegenerative and ocular diseases, nephrolithiasis, and diabetic neuropathy. Safety concerns and future directions are also mentioned, suggesting the critical examination of the exact mechanism of action, specific radical-scavenging capabilities of the blackcurrants and the crucial need for well-designed clinical trials to ensure the successful use of blackcurrants in a clinical setting.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1039/c2fo30058c" target="_blank" rel="noreferrer noopener">10.1039/c2fo30058c</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Health Promotion
*Ribes/chemistry
2012
Ahmed Shamima
Anthocyanins/analysis
Anti-Infective Agents
Anti-Inflammatory Agents
Antineoplastic Agents
Antioxidants
Bishayee Anupam
Darvesh Altaf S
Department of Pharmaceutical Sciences
Fatty Acids
Flavonoids/analysis
Food & function
Fruit/chemistry
Gopalan Ashwin
Hohmann Judit
Humans
NEOMED College of Pharmacy
Phytogenic
Phytotherapy
Plant Extracts/adverse effects/pharmacokinetics/pharmacology
Reuben Sharon C
Unsaturated/analysis
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0899-7071(01)00329-1" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0899-7071(01)00329-1</a>
Pages
303–308
Issue
5
Volume
25
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Can tamoxifen cause a significant mammographic density change in breast parenchyma?
Publisher
An entity responsible for making the resource available
Clinical imaging
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
2001-10
Subject
The topic of the resource
Aged; Antineoplastic Agents; Breast Neoplasms/*diagnostic imaging/*prevention & control/surgery; Breast/anatomy & histology/*drug effects; Computer-Assisted; Female; Hormonal/*pharmacology; Humans; Image Processing; Mammography; Tamoxifen/*pharmacology
Creator
An entity primarily responsible for making the resource
Konez O; Goyal M; Reaven R E
Description
An account of the resource
To evaluate tamoxifen-induced glandular tissue density changes in women who are on an adjuvant tamoxifen therapy. We examined serial mammograms of 27 women (average age 67) who had surgery for unilateral breast carcinoma and were on tamoxifen for 5 years. Mammograms obtained at the beginning of treatment, within 2 or 3 years, at the end of 5 years and 1 year after cessation of tamoxifen treatment, were evaluated by two radiologists experienced in reading mammograms. Four 1-cm-diameter circular areas of the glandular tissue and retroglandular fat were sampled by a densitometer and a relative glandular density (glandular tissue/fat density) was used for comparison between serial mammograms. Most cases (79%) did not show tamoxifen-induced change in glandular density. Three patients (13%) showed an early and two (8%) a delayed mild reduction in glandular density as compared to baseline mammograms. No patient was found to have increased glandular density following the cessation of tamoxifen therapy (in subjective evaluation). Densitometer readings showed a mild reduction in glandular densities in 16 cases (60%) during treatment and a minimal increase in 13 cases (48%) following cessation of treatment. There was a slight decrease in breast density during treatment [relative density of 0.012+/-0.006 (standard error) per interval, P value:.06] and the difference between years 5 and 6 was nearly zero [relative density of 0.00042+/-0.01 (standard error), P value:.97]. Long-term use of tamoxifen may cause a mild reduction in breast glandular density, although this, in part, may be attributed to the age-related mammographic density change. Following cessation of tamoxifen, no significant increase in glandular density was observed. Therefore, any increase in mammographic density during or after tamoxifen treatment should be viewed with suspicion and further evaluated.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0899-7071(01)00329-1" target="_blank" rel="noreferrer noopener">10.1016/s0899-7071(01)00329-1</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2001
Aged
Antineoplastic Agents
Breast Neoplasms/*diagnostic imaging/*prevention & control/surgery
Breast/anatomy & histology/*drug effects
Clinical imaging
Computer-Assisted
Female
Goyal M
Hormonal/*pharmacology
Humans
Image Processing
Konez O
Mammography
Reaven R E
Tamoxifen/*pharmacology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.bcp.2014.03.012" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.bcp.2014.03.012</a>
Pages
490–502
Issue
4
Volume
89
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
BCNU-induced gR2 defect mediates S-glutathionylation of Complex I and respiratory uncoupling in myocardium.
Publisher
An entity responsible for making the resource available
Biochemical pharmacology
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-06
Subject
The topic of the resource
Alkylating/*adverse effects/pharmacology; Animals; Antineoplastic Agents; Cardiotoxins/adverse effects/pharmacology; Carmustine/*adverse effects/pharmacology; Cattle; Cell Line; Complex I; Electron Transport Complex I/chemistry/*metabolism; Fatty Acids; Glutathione reductase; Glutathione Reductase/*antagonists & inhibitors/metabolism; Glutathione/*metabolism; Heart Ventricles/drug effects/metabolism/physiopathology; Heart/*drug effects/metabolism; Ion Channels/metabolism; Left/*chemically induced/metabolism/physiopathology; Male; Mice; Mitochondria; Mitochondrial Proteins/metabolism; Nonesterified/metabolism; Oxidative stress; Oxidative Stress/drug effects; Post-Translational/drug effects; Protein Processing; Rats; S-Glutathionylation; Sprague-Dawley; Superoxide Dismutase/genetics/metabolism; Systolic dysfunction; Transgenic; Uncoupling Protein 3; Ventricular Dysfunction
Creator
An entity primarily responsible for making the resource
Kang Patrick T; Chen Chwen-Lih; Ren Pei; Guarini Giacinta; Chen Yeong-Renn
Description
An account of the resource
A deficiency of mitochondrial glutathione reductase (or GR2) is capable of adversely affecting the reduction of GSSG and increasing mitochondrial oxidative stress. BCNU [1,3-bis (2-chloroethyl)-1-nitrosourea] is an anticancer agent and known inhibitor of cytosolic GR ex vivo and in vivo. Here we tested the hypothesis that a BCNU-induced GR2 defect contributes to mitochondrial dysfunction and subsequent impairment of heart function. Intraperitoneal administration of BCNU (40 mg/kg) specifically inhibited GR2 activity by 79.8 +/- 2.7% in the mitochondria of rat heart. However, BCNU treatment modestly enhanced the activities of mitochondrial Complex I and other ETC components. The cardiac function of BCNU-treated rats was analyzed by echocardiography, revealing a systolic dysfunction associated with decreased ejection fraction, decreased cardiac output, and an increase in left ventricular internal dimension and left ventricular volume in systole. The respiratory control index of isolated mitochondria from the myocardium was moderately decreased after BCNU treatment, whereas NADH-linked uncoupling of oxygen consumption was significantly enhanced. Extracellular flux analysis to measure the fatty acid oxidation of myocytes indicated a 20% enhancement after BCNU treatment. When the mitochondria were immunoblotted with antibodies against GSH and UCP3, both protein
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.bcp.2014.03.012" target="_blank" rel="noreferrer noopener">10.1016/j.bcp.2014.03.012</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2014
Alkylating/*adverse effects/pharmacology
Animals
Antineoplastic Agents
Biochemical pharmacology
Cardiotoxins/adverse effects/pharmacology
Carmustine/*adverse effects/pharmacology
Cattle
Cell Line
Chen Chwen-Lih
Chen Yeong-Renn
Complex I
Department of Integrative Medical Sciences
Electron Transport Complex I/chemistry/*metabolism
Fatty Acids
Glutathione reductase
Glutathione Reductase/*antagonists & inhibitors/metabolism
Glutathione/*metabolism
Guarini Giacinta
Heart Ventricles/drug effects/metabolism/physiopathology
Heart/*drug effects/metabolism
Ion Channels/metabolism
Kang Patrick T
Left/*chemically induced/metabolism/physiopathology
Male
Mice
Mitochondria
Mitochondrial Proteins/metabolism
NEOMED College of Medicine
Nonesterified/metabolism
Oxidative Stress
Oxidative Stress/drug effects
Post-Translational/drug effects
Protein Processing
Rats
Ren Pei
S-Glutathionylation
Sprague-Dawley
Superoxide Dismutase/genetics/metabolism
Systolic dysfunction
Transgenic
Uncoupling Protein 3
Ventricular Dysfunction
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ajog.2004.12.032" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ajog.2004.12.032</a>
Pages
1365–1367
Issue
5
Volume
192
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
Publisher
An entity responsible for making the resource available
American journal of obstetrics and gynecology
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-05
Subject
The topic of the resource
Adult; Aged; Antineoplastic Agents; Antineoplastic Agents/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Carboplatin/administration & dosage; Drug Administration Schedule; Endometrial Neoplasms/*drug therapy; Female; Humans; Local/drug therapy; Middle Aged; Neoplasm Recurrence; Paclitaxel/administration & dosage; Phytogenic/administration & dosage; Survival Analysis; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Akram Tahira; Maseelall Priya; Fanning James
Description
An account of the resource
OBJECTIVE: The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer. STUDY DESIGN: This was a retrospective review of 18 consecutive patients with advanced (stage 4) or recurrent endometrial adenocarcinoma that had been treated with outpatient carboplatin and taxol. Taxol was delivered at 135 mg/m 2 over 3 hours, and carboplatin was delivery at an area under the curve of 5 over 1 hour. Cycles were repeated every 21 days. RESULTS: The overall response rate was 63% with 28% of patients who had a partial response and 35% of patients who had a complete response. Kaplan-Meier test was used to estimate the median survival time of 27 months and the median progression free survival time of 24 months. No patient had neutropenia, thrombocytopenia or grade 3 vomiting, neurosensory toxicity, or renal toxicity. CONCLUSION: Carboplatin and taxol for the treatment of advanced or recurrent endometrial cancer appear to be active regimens with minimal toxicity.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ajog.2004.12.032" target="_blank" rel="noreferrer noopener">10.1016/j.ajog.2004.12.032</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2005
Adult
Aged
Akram Tahira
American journal of obstetrics and gynecology
Antineoplastic Agents
Antineoplastic Agents/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/administration & dosage
Drug Administration Schedule
Endometrial Neoplasms/*drug therapy
Fanning James
Female
Humans
Local/drug therapy
Maseelall Priya
Middle Aged
Neoplasm Recurrence
Paclitaxel/administration & dosage
Phytogenic/administration & dosage
Survival Analysis
Treatment Outcome